Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.

MLA

Brown, Landon C., et al. “Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with MCRPC Treated with Abiraterone or Enzalutamide.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 14, July 2021, pp. 4077–88. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-20-3471.

APA

Brown, L. C., Halabi, S., Schonhoft, J. D., Yang, Q., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Barnett, E. S., Carbone, E. A., Zhao, J. L., Healy, P., Anand, M., Gill, A., Jendrisak, A., Berry, W. R., Gupta, S., Gregory, S. G., … Armstrong, A. J. (2021). Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 27(14), 4077–4088. https://doi.org/10.1158/1078-0432.CCR-20-3471

Chicago

Brown, Landon C, Susan Halabi, Joseph D Schonhoft, Qian Yang, Jun Luo, David M Nanus, Paraskevi Giannakakou, et al. 2021. “Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with MCRPC Treated with Abiraterone or Enzalutamide.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27 (14): 4077–88. doi:10.1158/1078-0432.CCR-20-3471.